Methods and kits to predict therapeutic outcome of BTK inhibitors
US10322127B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2016 |
| Grant date | Jun 18, 2019 |
| Priority date | — |
| Expiry date | Aug 23, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.